KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Hims & Hers Health (HIMS) EBITDA (2020 - 2025)

Historic EBITDA for Hims & Hers Health (HIMS) over the last 6 years, with Q3 2025 value amounting to $15.9 million.

  • Hims & Hers Health's EBITDA fell 7911.04% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.5 million, marking a year-over-year increase of 3233.71%. This contributed to the annual value of $125.8 million for FY2024, which is 63793.02% up from last year.
  • According to the latest figures from Q3 2025, Hims & Hers Health's EBITDA is $15.9 million, which was down 7911.04% from $43.5 million recorded in Q2 2025.
  • Over the past 5 years, Hims & Hers Health's EBITDA peaked at $76.0 million during Q3 2024, and registered a low of -$51.5 million during Q1 2021.
  • For the 5-year period, Hims & Hers Health's EBITDA averaged around $2.0 million, with its median value being -$7.4 million (2023).
  • As far as peak fluctuations go, Hims & Hers Health's EBITDA plummeted by 85308.25% in 2021, and later skyrocketed by 193126.0% in 2024.
  • Hims & Hers Health's EBITDA (Quarter) stood at -$31.2 million in 2021, then skyrocketed by 65.69% to -$10.7 million in 2022, then skyrocketed by 111.7% to $1.3 million in 2023, then skyrocketed by 1931.26% to $25.5 million in 2024, then plummeted by 37.68% to $15.9 million in 2025.
  • Its EBITDA stands at $15.9 million for Q3 2025, versus $43.5 million for Q2 2025 and $49.6 million for Q1 2025.